Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.
All entries for: Xilio Therapeutics
May 8, 2025
Xilio Therapeutics
Negative Outlook
Waltham, MA
51-200 employees
Disease Area: Immune Diseases, Multiple, Oncology
Drug Type: Biologic
November 9, 2023
Xilio Therapeutics
Negative Outlook
Waltham, MA
51-200 employees
Disease Area: Oncology
Drug Type: Biologic
August 14, 2023
Xilio Therapeutics
Negative Outlook
Waltham, MA
51-200 employees
Disease Area: Oncology
Drug Type: Biologic
May 9, 2023
Xilio Therapeutics
Negative Outlook
Waltham, MA
51-200 employees
Disease Area: Oncology
Drug Type: Biologic
November 9, 2022
Xilio Therapeutics
Negative Outlook
Waltham, MA
51-200 employees
Note: Xilio described the IRA in a risk section entitled “Current and future legislative efforts may limit the prices for our products, if and when they are licensed for marketing, and that could materially impact our ability to generate revenues”
Disease Area: Oncology
Drug Type: Biologic